VELTIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5690923 | ALMIRALL | Stable topical retinoid compositions |
Nov, 2014
(9 years ago) | |
| US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 3 months from now) | |
Veltin is owned by Almirall.
Veltin contains Clindamycin Phosphate; Tretinoin.
Veltin has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Veltin are:
- US5690923
Veltin was authorised for market use on 16 July, 2010.
Veltin is available in gel;topical dosage forms.
Veltin can be used as treatment of atopic dermatitis.
The generics of Veltin are possible to be released after 31 August, 2025.
Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient
Market Authorisation Date: 16 July, 2010
Treatment: Treatment of atopic dermatitis
Dosage: GEL;TOPICAL
More Information on Dosage
VELTIN family patents
